Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. develops clinical-stage therapies for unmet medical needs, with news centered on pipeline progress, regulatory authorizations, intellectual property and financing activity. Company updates frequently cover HT-001, a topical therapeutic for EGFR inhibitor-associated skin toxicities in cancer patients, as well as HT-VA/GDNF metabolic research tied to obesity, MAFLD and related liver-fat pathways.
Other HOTH news themes include patent protection for mast-cell targeting splice-switching oligonucleotide technology, use of the OpenClaw AI-enabled platform for drug-discovery analysis, and capital formation through registered direct offerings and warrant issuances. The company’s public updates generally reflect early-stage pharmaceutical research moving from preclinical work into clinical development.
Hoth Therapeutics (NASDAQ:HOTH) plans to change its name to Rocket One and refocus on AI semiconductor infrastructure, ultra-low-power AI computing, and spintronic technologies while placing its biotechnology assets in a wholly owned subsidiary.
The company obtained exclusive rights to a non-volatile nanomagnetic matrix multiplier AI accelerator and a spintronic memory platform from VCU, targeting AI data center power demands, defense, aerospace, and space-based computing applications.
Hoth Therapeutics (NASDAQ: HOTH) secured regulatory authorization in Spain for its Phase 2a CLEER trial of HT-001 and reported interim data showing clinical benefit in cancer patients with EGFR-inhibitor skin toxicities.
Key interim findings: primary endpoint met (rash severity ARIGA ≤1 by Week 6), >65% reported reduced pain and itching, zero patients required EGFR inhibitor dose reductions or discontinuations, and no treatment-limiting adverse events observed.
Spain authorization supports continued randomized, placebo-controlled, dose-ranging study execution and planned European expansion.
Hoth Therapeutics (NASDAQ: HOTH) reported April 14, 2026 HT-VA preclinical data showing parenteral GDNF reprograms liver fat metabolism. Key findings include a statistically significant reduction in Srebf1 and an increase in Pparα, plus gene-expression improvements vs semaglutide.
The company plans additional preclinical validation, evaluation of clinical development paths for MAFLD and obesity, and potential partnerships to accelerate development.
Hoth Therapeutics (NASDAQ: HOTH) reported positive preclinical HT-VA CRADA data on April 13, 2026, showing parenteral GDNF reprograms liver fat metabolism at the genetic level.
Key findings include a statistically significant reduction in Srebf1 (lipogenesis), increased Pparα expression (fat burning), and gene-marker outperformance versus semaglutide. Hoth plans further preclinical validation and evaluation of clinical development and partnerships.
Hoth Therapeutics (Nasdaq: HOTH) closed a registered direct offering on April 2, 2026, selling 2,857,144 shares at $0.70 per share for gross proceeds of approximately $2.0 million. Concurrently, the company sold unregistered warrants exercisable at $0.85 after six months and expiring 5.5 years after issuance. H.C. Wainwright acted as placement agent. The company intends to use net proceeds for general corporate purposes, including working capital.
Hoth Therapeutics (Nasdaq: HOTH) agreed to sell 2,857,144 shares at $0.70 per share in a registered direct offering, raising approximately $2.0 million gross before fees. A concurrent private placement issued warrants to buy 2,857,144 shares at $0.85, exercisable six months after issuance and expiring 5.5 years later. Closing expected on or about April 2, 2026. Proceeds intended for general corporate purposes, including working capital; placement agent H.C. Wainwright & Co. is exclusive agent.
Hoth Therapeutics (NASDAQ: HOTH) reported that its HT-001 program met the primary efficacy endpoint in an interim analysis, with patients reaching an ARIGA ≤1 by week six. Over 65% of patients reported reduced pain and itching, with zero EGFR therapy disruptions and ~99% lower systemic exposure versus oral therapies. Hungary approved expansion of the Phase 2 trial into Europe, and site activations are expected soon in the U.S., Spain and Poland.
Hoth Therapeutics (NASDAQ: HOTH) announced that the China National Intellectual Property Administration granted a Chinese patent titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells".
The patent (PCT/US2019/048400), developed by North Carolina State University, provides protection in China through August 27, 2039, subject to maintenance requirements, and covers a splice-switching oligonucleotide platform that selectively induces mast cell apoptosis.
Hoth Therapeutics (NASDAQ: HOTH) announced deployment of OpenClaw™, an AI-enabled computational platform to accelerate drug discovery across its pipeline.
OpenClaw™ centralizes preclinical and clinical data in real time, standardizes workflows across dermatology, oncology and inflammatory programs, and is designed to speed candidate selection and increase probability of technical success, the company said.
Hoth Therapeutics (NASDAQ: HOTH) reported positive pharmacokinetic, safety, and clinical activity data for topical HT-001 on March 24, 2026. Key PK results: mean AUC₀–₂₄ rose to 80.60 h•ng/mL on Day 42 from 45.61 on Day 1 (~76.7% increase). Mean Cavg increased to 3.36 ng/mL and mean Cmax to 4.56 ng/mL. Accumulation ratios were RA_AUCτ ~2.09x and RA_Cmax ~1.72x. Systemic exposure remained minimal versus oral formulations (~0.2% Day 1, 0.5% Day 42). Safety: no serious adverse events, no dose-limiting toxicities, and no discontinuations due to adverse events. The company linked sustained exposure to observed symptom reductions and supports further development and dose optimization.